REGENERON PHARMACEUTICALS,INC. (NASDAQ:REGN) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

REGENERON PHARMACEUTICALS,INC. (NASDAQ:REGN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2017 Annual Meeting of Shareholders of the Company held on June9, 2017, Regeneron’s shareholders voted, among other matters, on a proposal on the frequency of future advisory shareholder votes on executive compensation. As reported by the Company in the Original Report, a frequency of every three years received a majority of the votes cast on the proposal. Based on these results and the recommendation of the Compensation Committee and the Corporate Governance and Compliance Committee, Regeneron’s Board of Directors determined that future advisory shareholder votes on executive compensation continue to be held once every three years.


About REGENERON PHARMACEUTICALS,INC. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.